to provide all three distributors ….

to provide all three distributors and state regulators with aggregated data and analytics about where drugs are going and how often, eliminating blind spots in the current systems used by distributors;

•Use data-driven systems to detect suspicious opioid orders from customer pharmacies; •Terminate customer pharmacies’ ability to receive shipments, and report those companies to state regulators, when they show certain signs of diversion;

•Prohibit shipping of and report suspicious opioid orders; •Prohibit sales staff from influencing decisions related to identifying suspicious opioid orders; and

•Require senior corporate officials to engage in regular oversight of anti-diversion efforts.

Johnson & Johnson is required to:

•Stop selling opioids;

•Not fund or provide grants to third parties for promoting opioids;

•Not lobby on activities related to opioids; and

•Share clinical trial data under the Yale University Open Data Access Project.

Following successful state sign-on and subdivision signon periods, the defendants will start releasing funds to a national administrator on April 2. Money will start flowing to state and local governments in the second quarter of 2022. This is the second largest multistate agreement in U.S. history, second only to the Tobacco Master Settlement Agreement.